Stock Market & Financial Investment News

News For AMRN;GSK From The Last 14 Days Check below for free stories on AMRN;GSK the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 08:25 EDT GSK GlaxoSmithKline awarded up to $200M by U.S. to develop new antibiotics Subscribe for More Information 06:07 EDT AMRN Amarin announces patent allowance related to combination of Vascepa, Statin Amarin announced that the United States Patent and Trademark Office has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa indication approved by the FDA based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy. The claims in this allowed application cover a method to reduce triglycerides in subjects having a triglyceride level of 500mg/dl to 1500mg/dl who are also receiving statin therapy using an amount of Vascepa effective to reduce triglycerides without substantially increasing low density lipoprotein cholesterol. May 21, 2013 11:41 EDT AMRN Options with decreasing implied volatility: SGMO WCRX NTI TSLA AMRN 07:44 EDT GSK Sachs Associates to host a forum Subscribe for More Information 07:07 EDT GSK Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray Subscribe for More Information May 17, 2013 14:12 EDT AMRN Amarin shares slip after FDA updates Orange Book Subscribe for More Information May 15, 2013 11:04 EDT AMRN Amarin management to meet with Lazard Capital Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. May 14, 2013 07:24 EDT GSK EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 13, 2013 16:25 EDT GSK On The Fly: Closing Wrap Stocks on Wall Street were little changed from their opening levels as investors weighed the potential end of the Fed's quantitative easing program against a better than expected report on retail sales. The Wall Street Journal's Jon Hilsenrath suggested in a report over the weekend that the Federal Reserve has mapped a QE exit strategy. The report paired with the retail sales data left the market lacking conviction in either direction today, as the averages spent the majority of the session range-bound near the flatline. ECONOMIC EVENTS: In the U.S., retail sales rose 0.1% in April, which beat expectations for a 0.3% decline. Retail sales excluding autos, gas, and building materials rose 0.6%, which was also better than expected. Business inventories were flat in March, versus expectations for a 0.3% gain. In Asia, Chinese factory output grew 9.3% annually in April, which was up from 8.9% in March but still missed expectations for a 9.5% growth rate. COMPANY NEWS: The Supreme Court ruled unanimously that Monsanto's (MON) patented genetically altered soybeans are protected and that farmers cannot use them to create new seeds without paying the company... Dell's (DELL) special committee publicly asked for more information from Carl Icahn and Southeastern Asset Management about their proposed leveraged recapitalization. This request follows television interviews by Icahn last Friday in which he discussed his Dell proposal, as well as a weekend report in Barron's saying the Icahn and Southeastern plan could be a better deal for shareholders. MAJOR MOVERS: Among the notable gainers was Theravance (THRX), up $6.26, or 17.92%, to $41.20 after Elan Corporation (ELN) bought a stake in the potential future royalty payments from four respiratory programs partnered with GlaxoSmithKline (GSK) in exchange for $1B in cash. Also higher was Tesla (TSLA), which rose $11.04, or 14.38%, to $87.80 in its third straight double-digit percentage gain following a better-than-expected earnings report last week. Among the noteworthy losers was Barnes & Noble (BKS), down $2.21, or 9.48%, to $21.10 after the blog InsiderMonkey disputed a previous report about Microsoft's (MSFT) interest in the bookseller's NOOK assets. Also lower was JoS. A. Bank (JOSB), down $3.31, or 7.16%, to $42.90 after the company's first quarter earnings view came in below expectations. INDICES: The Dow was down 26.81, or 0.18%, to 15,091.68; the Nasdaq was up 2.21, or 0.06%, to 3,438.79; and the S&P 500 was nearly unchanged at 1,633.77. 12:52 EDT AMRN Amarin strength attributed to MassHealth drug list addition Subscribe for More Information 12:20 EDT GSK On The Fly: Midday Wrap Subscribe for More Information 05:44 EDT GSK Elan provides additional information on Elan/Theravance agreement Subscribe for More Information 05:35 EDT GSK Theravance, Elan enter into $1B royalty participation agreement Subscribe for More Information May 10, 2013 12:42 EDT GSK GlaxoSmithKline, Theravance confirm FDA approval of Breo Ellipta Subscribe for More Information 11:48 EDT GSK Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 11:15 EDT GSK FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease Subscribe for More Information 09:23 EDT AMRN Amarin continues to make progress with payors, says Leerink Leerink reiterates an Outperform rating on shares of Amarin following the company's Q1 results. The firm believes Amarin continues to make good progress with payors and that Vascepa script trends are tracking well. 06:53 EDT GSK GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says Subscribe for More Information May 9, 2013 16:18 EDT AMRN Amarin reports Q1 EPS (41c), consensus (39c) Reports Q1 revenue $2.34M, consensus $5.2M. Amarin said its direct sales force, consisting of approximately 275 sales professionals, made sales calls to clinicians for two months in Q1. Amarin reports that, since launch, access to clinicians has been good, and that it has yet to hear any significant negative reaction to the efficacy or safety profile of Vascepa. Amarin said it continues to make significant progress in its effort to expand patent protection for Vascepa and now has 22 patents issued or allowed in the United States with over 30 additional U.S. patent applications being prosecuted. 13:15 EDT AMRN Amarin, Omthera drop following fatty acids study in journal Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.